JP4902900B2 - 少なくとも２つのシェルに包まれた酸化鉄含有コアを有するナノスケール粒子 - Google Patents
少なくとも２つのシェルに包まれた酸化鉄含有コアを有するナノスケール粒子 Download PDFInfo
- Publication number
- JP4902900B2 JP4902900B2 JP50378399A JP50378399A JP4902900B2 JP 4902900 B2 JP4902900 B2 JP 4902900B2 JP 50378399 A JP50378399 A JP 50378399A JP 50378399 A JP50378399 A JP 50378399A JP 4902900 B2 JP4902900 B2 JP 4902900B2
- Authority
- JP
- Japan
- Prior art keywords
- core
- nanoscale particles
- nanoscale
- shell
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 46
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 239000002245 particle Substances 0.000 claims abstract description 53
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 241000282414 Homo sapiens Species 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 125000002091 cationic group Chemical group 0.000 claims abstract description 8
- 241000894007 species Species 0.000 claims abstract description 8
- 206010020843 Hyperthermia Diseases 0.000 claims abstract description 4
- 230000036031 hyperthermia Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 13
- 238000009826 distribution Methods 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 3
- 238000006068 polycondensation reaction Methods 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 238000009827 uniform distribution Methods 0.000 claims description 2
- 238000004299 exfoliation Methods 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 abstract description 12
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 125000000129 anionic group Chemical group 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 239000011257 shell material Substances 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 31
- 210000004881 tumor cell Anatomy 0.000 description 21
- 235000013980 iron oxide Nutrition 0.000 description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 230000005284 excitation Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000020169 heat generation Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- -1 6-aminohexyl Chemical group 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- 125000003700 epoxy group Chemical group 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000004020 intracellular membrane Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910000077 silane Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- ZDZYGYFHTPFREM-UHFFFAOYSA-N 3-[3-aminopropyl(dimethoxy)silyl]oxypropan-1-amine Chemical compound NCCC[Si](OC)(OC)OCCCN ZDZYGYFHTPFREM-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910001566 austenite Inorganic materials 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- NHBRUUFBSBSTHM-UHFFFAOYSA-N n'-[2-(3-trimethoxysilylpropylamino)ethyl]ethane-1,2-diamine Chemical compound CO[Si](OC)(OC)CCCNCCNCCN NHBRUUFBSBSTHM-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- HQYALQRYBUJWDH-UHFFFAOYSA-N trimethoxy(propyl)silane Chemical compound CCC[Si](OC)(OC)OC HQYALQRYBUJWDH-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hard Magnetic Materials (AREA)
- Compounds Of Iron (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19726282A DE19726282A1 (de) | 1997-06-20 | 1997-06-20 | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
| DE19726282.1 | 1997-06-20 | ||
| PCT/EP1998/003761 WO1998058673A1 (de) | 1997-06-20 | 1998-06-19 | Nanoskalige teilchen mit einem von mindestens zwei schalen umgebenen eisenoxid-haltigen kern |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009210228A Division JP5116743B2 (ja) | 1997-06-20 | 2009-09-11 | 少なくとも２つのシェルに包まれた酸化鉄含有コアを有するナノスケール粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002507964A JP2002507964A (ja) | 2002-03-12 |
| JP2002507964A5 JP2002507964A5 (enExample) | 2006-01-05 |
| JP4902900B2 true JP4902900B2 (ja) | 2012-03-21 |
Family
ID=7833178
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50378399A Expired - Fee Related JP4902900B2 (ja) | 1997-06-20 | 1998-06-19 | 少なくとも２つのシェルに包まれた酸化鉄含有コアを有するナノスケール粒子 |
| JP2009210228A Expired - Fee Related JP5116743B2 (ja) | 1997-06-20 | 2009-09-11 | 少なくとも２つのシェルに包まれた酸化鉄含有コアを有するナノスケール粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009210228A Expired - Fee Related JP5116743B2 (ja) | 1997-06-20 | 2009-09-11 | 少なくとも２つのシェルに包まれた酸化鉄含有コアを有するナノスケール粒子 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6541039B1 (enExample) |
| EP (1) | EP1001811B1 (enExample) |
| JP (2) | JP4902900B2 (enExample) |
| CN (1) | CN1211127C (enExample) |
| AT (1) | ATE223731T1 (enExample) |
| DE (2) | DE19726282A1 (enExample) |
| DK (1) | DK1001811T3 (enExample) |
| ES (1) | ES2181256T3 (enExample) |
| PT (1) | PT1001811E (enExample) |
| WO (1) | WO1998058673A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010001308A (ja) * | 1997-06-20 | 2010-01-07 | Leibniz-Inst Fuer Neue Materialien Gemeinnuetzige Gmbh | 少なくとも２つのシェルに包まれた酸化鉄含有コアを有するナノスケール粒子 |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306166B1 (en) * | 1997-08-13 | 2001-10-23 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
| DE19921088C2 (de) * | 1999-04-30 | 2003-08-07 | Magforce Applic Gmbh | Stent zur Offenhaltung gangartiger Strukturen |
| DE19924138A1 (de) | 1999-05-26 | 2000-11-30 | Henkel Kgaa | Lösbare Klebeverbindungen |
| DE19940220B4 (de) | 1999-08-19 | 2007-05-03 | Magforce Nanotechnologies Ag | Medizinisches Präparat zur Behandlung von Arthrose, Arthritis und anderen rheumatischen Gelenkerkrankungen |
| DE50015289D1 (de) * | 1999-08-24 | 2008-09-11 | Henkel Ag & Co Kgaa | Verklebung durch Klebstoffe enthaltend nanoskalige Teilchen |
| DE19951599A1 (de) | 1999-10-27 | 2001-05-23 | Henkel Kgaa | Verfahren zur adhesiven Trennung von Klebeverbunden |
| EP2343047B2 (en) | 2000-02-08 | 2021-03-17 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| DE10020376A1 (de) * | 2000-04-26 | 2001-11-08 | Inst Zelltechnologie E V | Dynamische Marker |
| DE10037883A1 (de) | 2000-08-03 | 2002-02-14 | Henkel Kgaa | Ferromagnetische Resonanzanregung und ihre Verwendung zur Erwärmung teilchengefüllter Substrate |
| DE10037884A1 (de) | 2000-08-03 | 2002-02-21 | Henkel Kgaa | Verfahren zur beschleunigten Klebstoffaushärtung |
| DE10141674A1 (de) | 2000-09-01 | 2002-03-14 | Henkel Kgaa | Reaktionsklebstoff mit mindestens einer mikroverkapselten Komponente |
| US6997863B2 (en) * | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US7074175B2 (en) * | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US7951061B2 (en) * | 2001-07-25 | 2011-05-31 | Allan Foreman | Devices for targeted delivery of thermotherapy, and methods related thereto |
| US7731648B2 (en) * | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
| US20050013875A1 (en) * | 2001-10-25 | 2005-01-20 | Takeshi Kobayashi | Immunopotentiators in thermotherapy for cancer |
| DE10163399A1 (de) | 2001-12-21 | 2003-07-10 | Sustech Gmbh & Co Kg | Nanopartikuläre Zubereitung |
| DE10205332B4 (de) * | 2002-02-06 | 2004-02-12 | Berlin Heart Ag | Verfahren zur Herstellung von magnetischen Nanoteilchen |
| AU2002361032A1 (en) * | 2002-12-09 | 2004-06-30 | Itn-Nanovation Gmbh | Nanoscale core/shell particles and the production thereof |
| AU2003900335A0 (en) * | 2003-01-22 | 2003-02-13 | Sirtex Medical Limited | Microparticles for selectively targeted hyperthermia |
| DE10331439B3 (de) | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetische Nanopartikel mit verbesserten Magneteigenschaften |
| US20050107870A1 (en) * | 2003-04-08 | 2005-05-19 | Xingwu Wang | Medical device with multiple coating layers |
| US20050119725A1 (en) * | 2003-04-08 | 2005-06-02 | Xingwu Wang | Energetically controlled delivery of biologically active material from an implanted medical device |
| DE10326538A1 (de) * | 2003-06-12 | 2005-01-05 | Institut für Neue Materialien Gemeinnützige GmbH | Abriebfeste optische Schichten und Formkörper |
| DE10344449A1 (de) * | 2003-09-25 | 2005-04-28 | Henkel Kgaa | Klebstoff-Zusammensetzung mit Barriere-Eigenschaften |
| US20050090732A1 (en) * | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| DE10359252A1 (de) * | 2003-12-17 | 2005-07-28 | Siemens Ag | Navigierte Wärmebehandlung von Tumoren mit enzymumhüllten Eisenpartikeln |
| US20060018835A1 (en) * | 2004-04-02 | 2006-01-26 | General Electric Company | Nanoparticles with inorganic core and methods of using them |
| US7407816B2 (en) | 2004-05-07 | 2008-08-05 | Gentius, Inc | Isoelectric particles and uses thereof |
| US7842281B2 (en) * | 2004-05-10 | 2010-11-30 | The Florida State University Research Foundation | Magnetic particle composition for therapeutic hyperthermia |
| US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
| US20050260137A1 (en) * | 2004-05-18 | 2005-11-24 | General Electric Company | Contrast agents for magnetic resonance imaging |
| DE102004038274A1 (de) * | 2004-08-06 | 2006-03-16 | Henkel Kgaa | Bindemittel mit Barriere-Eigenschaften II |
| EP1803467A1 (en) * | 2004-08-25 | 2007-07-04 | Kagoshima University | Composite fine particles and process for producing the same |
| DE102004052533A1 (de) † | 2004-10-15 | 2006-05-04 | Mykhaylyk, Olga, Dr. | Magnetische Partikel zur Verwendung in Therapie und Diagnostik |
| DE102005016873A1 (de) | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
| JP2008545665A (ja) * | 2005-05-23 | 2008-12-18 | ユニベルシテ ドゥ ジュネーブ | 高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用 |
| DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| DE102005060834A1 (de) | 2005-12-20 | 2007-06-28 | Grönemeyer Holding GmbH & Co. KG | Magnetfeldapplikator |
| DE102006007564A1 (de) * | 2006-02-16 | 2007-08-30 | Röhm Gmbh | Nanoskalige superparamagnetische Poly(meth)acrylatpolymere |
| JP2009527472A (ja) | 2006-02-17 | 2009-07-30 | トパス ゲーエムベーハー | 細胞特異性を有する三区画ポリマーナノ粒子を使用した多モード撮像法概要 |
| WO2007115291A2 (en) * | 2006-04-04 | 2007-10-11 | Freedom-2, Inc. | Tissue markings with discrete absorption particles |
| EP1852107A1 (en) * | 2006-04-19 | 2007-11-07 | Nanobiotix | Magnetic nanoparticles compositions and uses thereof |
| US20070281031A1 (en) * | 2006-06-01 | 2007-12-06 | Guohan Yang | Microparticles and methods for production thereof |
| US9277295B2 (en) * | 2006-06-16 | 2016-03-01 | Cisco Technology, Inc. | Securing media content using interchangeable encryption key |
| JP5001364B2 (ja) * | 2006-07-04 | 2012-08-15 | ブラッコ イメージング ソチエタ ペル アチオニ | 腫瘍性組織等の生物組織を局部的に熱剥離するための装置 |
| EP2056883B1 (en) | 2006-08-04 | 2021-09-22 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| KR101489830B1 (ko) * | 2006-12-18 | 2015-02-04 | 콜로로삐아 이탈리아 에스.피.에이 | 발열요법에 적용하기 위한 자성 나노 입자, 그의 제조 및 약리 적용을 갖는 구조체에의 용도 |
| US20080167548A1 (en) * | 2007-01-04 | 2008-07-10 | Sorensen Alma G | Tissue Alteration With MRI RF Field |
| US20110104073A1 (en) * | 2007-01-18 | 2011-05-05 | Qi Zeng | Iron/Iron Oxide Nanoparticle and Use Thereof |
| NZ588816A (en) | 2007-01-21 | 2011-11-25 | Hemoteq Ag | Medical device for the treatment of stenoses of corporal lumina and for the prevention of impending restenoses |
| US20080281386A1 (en) * | 2007-05-09 | 2008-11-13 | Tessaron Medical, Inc. | Systems and methods for treating body tissue |
| US20080281318A1 (en) * | 2007-05-09 | 2008-11-13 | Tessaron Medical, Inc. | Systems and methods for inductive heat treatment of body tissue |
| US20090005734A1 (en) * | 2007-06-27 | 2009-01-01 | Tessaron Medical, Inc. | Systems and methods for delivering particles into patient body |
| US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
| ES2320837B1 (es) * | 2007-07-26 | 2010-03-04 | Consejo Superior De Investigaciones Cientificas | Dispositivo de hipertermia y su utilizacion con nanoparticulas. |
| US20090157069A1 (en) * | 2007-12-06 | 2009-06-18 | Curtis Tom | Systems and methods for thermal treatment of body tissue |
| DE102008003615A1 (de) | 2008-01-09 | 2009-07-16 | Magforce Nanotechnologies Ag | Magnetische Transducer |
| DE102008008522A1 (de) | 2008-02-11 | 2009-08-13 | Magforce Nanotechnologies Ag | Implantierbare Nanopartikel-enthaltende Produkte |
| KR101101832B1 (ko) | 2008-05-20 | 2012-01-05 | 연세대학교 산학협력단 | 열방출 나노 물질 |
| US8323685B2 (en) * | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US8323615B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing multi-phasic dispersions |
| US8367427B2 (en) | 2008-08-20 | 2013-02-05 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| DE102008064036B4 (de) * | 2008-12-22 | 2012-06-06 | Heraeus Medical Gmbh | Polymethylmethacrylat-Knochenzement-Zusammensetzung zur kontrollierten Hyperthermiebehandlung und deren Verwendung |
| WO2010102066A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Dextran polymer powder for inhalation administration of pharmaceuticals |
| US8293213B2 (en) * | 2009-03-12 | 2012-10-23 | Palo Alto Research Center Incorporated | Method and apparatus for thrombus removal using magnetic particles |
| EP2246376B1 (en) * | 2009-04-27 | 2014-03-05 | Leibniz-Institut für Polymerforschung Dresden e.V. | Method for preparing particles with a conjugated polymer shell |
| US10369256B2 (en) | 2009-07-10 | 2019-08-06 | Boston Scientific Scimed, Inc. | Use of nanocrystals for drug delivery from a balloon |
| EP2453938B1 (en) * | 2009-07-17 | 2015-08-19 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
| US9205155B2 (en) | 2009-10-30 | 2015-12-08 | General Electric Company | Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents |
| US8565892B2 (en) * | 2009-10-31 | 2013-10-22 | Qteris, Inc. | Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment |
| CA2777841C (en) | 2009-11-02 | 2017-01-17 | Francis M. Creighton | Magnetomotive stator system and methods for wireless control of magnetic rotors |
| DE102009058769A1 (de) | 2009-12-16 | 2011-06-22 | MagForce Nanotechnologies AG, 10589 | Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung |
| US20110160645A1 (en) * | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
| US20120021010A1 (en) * | 2010-04-29 | 2012-01-26 | University Of Calcutta | Antiplatelet agent and methods of using the same |
| US9669200B2 (en) | 2010-08-06 | 2017-06-06 | Boston Scientific Scimed, Inc. | Systems and methods for the treatment of pelvic disorders including magnetic particulates |
| US8889211B2 (en) | 2010-09-02 | 2014-11-18 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
| US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
| KR101173867B1 (ko) | 2010-10-28 | 2012-08-14 | 삼성에스디아이 주식회사 | 리튬 이차 전지 |
| US9180172B2 (en) | 2010-12-15 | 2015-11-10 | Ams Research Corporation | Treatment of Peyronies disease |
| US8979797B2 (en) | 2010-12-16 | 2015-03-17 | Ams Research Corporation | High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics |
| CA2833413C (en) | 2011-04-20 | 2020-09-22 | The University Of Sydney | A method for the treatment of a solid tumour |
| US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
| US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
| ES2582283T3 (es) | 2011-08-10 | 2016-09-12 | Magforce Ag | Dispositivo médico que comprende aglomerados de nanopartículas magnéticas recubiertas con alcoxisilano |
| WO2013021039A1 (en) | 2011-08-11 | 2013-02-14 | Basf Se | Microwave absorbing composition |
| WO2013028208A1 (en) | 2011-08-25 | 2013-02-28 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
| MX362089B (es) | 2011-12-16 | 2019-01-07 | Nanobiotix | Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos. |
| CN104204082B (zh) * | 2012-02-07 | 2016-08-24 | 国立大学法人筑波大学 | 高分子化氮氧化合物与无机颗粒的有机-无机杂合复合物 |
| US9883878B2 (en) | 2012-05-15 | 2018-02-06 | Pulse Therapeutics, Inc. | Magnetic-based systems and methods for manipulation of magnetic particles |
| WO2014008378A1 (en) * | 2012-07-06 | 2014-01-09 | Mtd Products Inc | Drive sprocket for a tracked utility vehicle |
| US9884662B2 (en) | 2013-09-13 | 2018-02-06 | Mtd Products Inc | Suspension and lock-out systems for a partially tracked vehicle |
| EP3044081B1 (en) | 2013-09-13 | 2020-04-15 | MTD Products Inc. | Drive sprocket for a tracked vehicle |
| WO2015056960A1 (ko) | 2013-10-16 | 2015-04-23 | 주식회사 지니스 | 전자기파를 이용한 암 온열치료용 감작제 조성물 및 이를 이용한 암 치료 방법 |
| US9902441B2 (en) | 2014-08-21 | 2018-02-27 | Mtd Products Inc | Track drive |
| EA201792560A1 (ru) | 2015-05-28 | 2018-06-29 | Нанобиотикс | Наночастицы для применения в качестве терапевтической вакцины |
| AU2016271322A1 (en) | 2015-05-29 | 2017-12-07 | Mtd Products Inc | Utility vehicle |
| US11147874B2 (en) | 2015-06-15 | 2021-10-19 | Boston Scientific Scimed, Inc. | Devices and methods for therapeutic heat treatment |
| DE102016006320A1 (de) | 2016-05-25 | 2017-11-30 | Carl Freudenberg Kg | Fixierbare Flächengebilde |
| JP7051483B2 (ja) * | 2017-03-29 | 2022-04-11 | 三洋化成工業株式会社 | マイクロ波加熱溶着用樹脂組成物 |
| US11511818B2 (en) | 2017-09-05 | 2022-11-29 | Mtd Products Inc | Track drive |
| AU2018346586A1 (en) | 2017-10-06 | 2020-03-12 | Mtd Products Inc | High-efficiency lawn maintenance tool and high-efficiency cutting blade |
| US11918315B2 (en) | 2018-05-03 | 2024-03-05 | Pulse Therapeutics, Inc. | Determination of structure and traversal of occlusions using magnetic particles |
| US12171443B1 (en) | 2021-03-09 | 2024-12-24 | Pulse Therapeutics, Inc. | Magnetically controlled flow generation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4827945A (en) * | 1986-07-03 | 1989-05-09 | Advanced Magnetics, Incorporated | Biologically degradable superparamagnetic materials for use in clinical applications |
| FR2618084B1 (fr) * | 1987-07-15 | 1989-11-10 | Rhone Poulenc Chimie | Microspheres magnetisables a base de polysiloxane, leur procede de preparation et leur application en biologie |
| EP0381742B1 (en) * | 1988-08-04 | 1996-06-19 | Advanced Magnetics Incorporated | Receptor mediated endocytosis type mri contrast agents |
| US5460831A (en) * | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
| US5462751A (en) * | 1990-06-22 | 1995-10-31 | The Regeants Of The University Of California | Biological and pharmaceutical agents having a nanomeric biodegradable core |
| DE4026978A1 (de) * | 1990-08-25 | 1992-02-27 | Bayer Ag | Auf traegern angebrachte ein- oder mehrlagige schichtelemente und ihre herstellung |
| US5616311A (en) * | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
| ATE207727T1 (de) * | 1992-05-29 | 2001-11-15 | Univ California | Beschichtetes transplantat sowie herstellungsverfahren dafür |
| WO1994010983A1 (fr) * | 1992-11-06 | 1994-05-26 | Hisamitsu Pharmaceutical Co., Inc. | Preparation pharmaceutique perorale liberable dans le tube digestif inferieur |
| US5547748A (en) * | 1994-01-14 | 1996-08-20 | Sri International | Carbon nanoencapsulates |
| US6103379A (en) * | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
| GB9420390D0 (en) * | 1994-10-10 | 1994-11-23 | Nycomed Salutar Inc | Liposomal agents |
| US6022500A (en) * | 1995-09-27 | 2000-02-08 | The United States Of America As Represented By The Secretary Of The Army | Polymer encapsulation and polymer microsphere composites |
| DE19614136A1 (de) * | 1996-04-10 | 1997-10-16 | Inst Neue Mat Gemein Gmbh | Verfahren zur Herstellung agglomeratfreier nanoskaliger Eisenoxidteilchen mit hydrolysebeständigem Überzug |
| US5922537A (en) * | 1996-11-08 | 1999-07-13 | N.o slashed.AB Immunoassay, Inc. | Nanoparticles biosensor |
| DE19726282A1 (de) * | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
-
1997
- 1997-06-20 DE DE19726282A patent/DE19726282A1/de not_active Withdrawn
-
1998
- 1998-06-19 DK DK98939520T patent/DK1001811T3/da active
- 1998-06-19 PT PT98939520T patent/PT1001811E/pt unknown
- 1998-06-19 JP JP50378399A patent/JP4902900B2/ja not_active Expired - Fee Related
- 1998-06-19 AT AT98939520T patent/ATE223731T1/de active
- 1998-06-19 WO PCT/EP1998/003761 patent/WO1998058673A1/de not_active Ceased
- 1998-06-19 EP EP98939520A patent/EP1001811B1/de not_active Expired - Lifetime
- 1998-06-19 US US09/446,438 patent/US6541039B1/en not_active Expired - Lifetime
- 1998-06-19 CN CNB988063018A patent/CN1211127C/zh not_active Expired - Fee Related
- 1998-06-19 DE DE59805535T patent/DE59805535D1/de not_active Expired - Lifetime
- 1998-06-19 ES ES98939520T patent/ES2181256T3/es not_active Expired - Lifetime
-
2003
- 2003-03-17 US US10/391,356 patent/US6979466B2/en not_active Expired - Fee Related
-
2009
- 2009-09-11 JP JP2009210228A patent/JP5116743B2/ja not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010001308A (ja) * | 1997-06-20 | 2010-01-07 | Leibniz-Inst Fuer Neue Materialien Gemeinnuetzige Gmbh | 少なくとも２つのシェルに包まれた酸化鉄含有コアを有するナノスケール粒子 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1260724A (zh) | 2000-07-19 |
| US6979466B2 (en) | 2005-12-27 |
| DE19726282A1 (de) | 1998-12-24 |
| US20030180370A1 (en) | 2003-09-25 |
| US6541039B1 (en) | 2003-04-01 |
| EP1001811B1 (de) | 2002-09-11 |
| DK1001811T3 (da) | 2003-01-20 |
| ES2181256T3 (es) | 2003-02-16 |
| EP1001811A1 (de) | 2000-05-24 |
| CN1211127C (zh) | 2005-07-20 |
| JP2010001308A (ja) | 2010-01-07 |
| DE59805535D1 (de) | 2002-10-17 |
| WO1998058673A1 (de) | 1998-12-30 |
| ATE223731T1 (de) | 2002-09-15 |
| PT1001811E (pt) | 2003-01-31 |
| JP5116743B2 (ja) | 2013-01-09 |
| JP2002507964A (ja) | 2002-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4902900B2 (ja) | 少なくとも２つのシェルに包まれた酸化鉄含有コアを有するナノスケール粒子 | |
| Li et al. | Design of smart size‐, surface‐, and shape‐switching nanoparticles to improve therapeutic efficacy | |
| Cheng et al. | Advances in nanomaterial-based targeted drug delivery systems | |
| Vallabani et al. | Recent advances and future prospects of iron oxide nanoparticles in biomedicine and diagnostics | |
| Kakar et al. | Magnetic microspheres as magical novel drug delivery system: A review | |
| Mo et al. | Ultrasound-enhanced drug delivery for cancer | |
| Huber et al. | In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound | |
| Melancon et al. | Cancer theranostics with near-infrared light-activatable multimodal nanoparticles | |
| Awad et al. | Effect of pegylation and targeting moieties on the ultrasound-mediated drug release from liposomes | |
| van Rooij et al. | Targeted ultrasound contrast agents for ultrasound molecular imaging and therapy | |
| Ng et al. | Therapeutic ultrasound: its application in drug delivery | |
| US6352683B1 (en) | Apparatus and method for the local delivery of drugs | |
| Pitt et al. | Ultrasonic drug delivery–a general review | |
| Kairemo et al. | Nanoparticles in cancer | |
| KR20130098441A (ko) | 나노입자 활성성분 결합물 | |
| EP2376125B1 (en) | Erythrocyte-based delivery system, method of preparation and uses thereof | |
| Subhan | Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics | |
| Chu et al. | Biomaterials with cancer cell-specific cytotoxicity: challenges and perspectives | |
| Hua et al. | Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research | |
| Liu et al. | Chemo-drug controlled-release strategies of nanocarrier in the development of cancer therapeutics | |
| Shrivastava et al. | Magnetically responsive polymeric gels and elastomeric system (s) for drug delivery | |
| Zhou et al. | Navigating therapeutic opportunities and challenges with micro/nanomotors in translational medicine: a review | |
| Qian et al. | Current applications of nanomaterials in urinary system tumors | |
| Altintas | Applications of magnetic nanomaterials in biosensors and diagnostics | |
| Pauwels et al. | Nanoparticles in cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20050308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050415 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080701 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080922 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090512 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120104 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150113 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |